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Background: : RR interval variations lead to beat-to-beat blood pressure differences through the myocardial
force–interval relationship (FIR). In sinus rhythm, an altered FIR leads to post-extrasystolic potentiation (PESP)
of systolic blood pressure, which has been shown to predict adverse outcome in survivors of acute myocardial
infarction (MI). The purpose of this study was (1) to develop a parameter to assess the FIR in patients with atrial
ﬁbrillation (AF) and (2) to investigate its association with mortality in MI survivors suffering from AF.
Methods and results: : Thirty-two patients with acute MI and AF underwent 30-min recordings of ECG and con-
tinuous blood pressure. Episodes of a short RR interval (b80% of mean interval, RRi) preceding a long interval
(N140%, RRi + 1) were identiﬁed. The systolic pressures of the pulsewaves following RRi and RRi + 1were labeled
Pi and Pi + 1. PESPAﬁb was calculated as (Pi + 1− Pi) / (RRi + 1− RRi).
During 5 years of follow-up, 13 patients died. When PESPAﬁb was dichotomized at the median, mortality rates
were 63% and 19% in patients with high and low PESPAﬁb. Hazard ratio for mortality was 4.88 for patients with
high PESPAﬁb (1.33–17.84, p = 0.004). The association of PESPAﬁb and mortality was independent from LVEF,
age, diabetes mellitus or mean heart rate.
Conclusions: : PESPAﬁb, ameasure for the FIR in patientswith AF, can be derived from simultaneous ECG and blood
pressure recordings. The results of this pilot study indicate that PESPAﬁbmay be useful to predict adverse outcome
in survivors of myocardial infarction suffering from AF.© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It has been known for more than a century that the contractile force
of the ﬁrst heartbeat after a premature ventricular contraction (PVC) is
augmented [1,2]. This phenomenon is termed post-extrasystolic poten-
tiation (PESP) [3,4]. Recently, we reported that PESP, measured at the
blood pressure level, is a powerful and independent predictor ofmortal-
ity in survivors of myocardial infarction (MI) [5].
Substantial beat-to-beat variations of RR interval durations, similar
in their extent to PVC coupling intervals and compensatory pauses,
occur also during atrial ﬁbrillation (AF). This allows one to modify the
concept of PESP for evaluating beat-to-beat blood pressure changes dur-
ing AF (PESPAﬁb). RR sequences of a short interval followed by a longability and freedom from bias of
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land Ltd. This is an open access articlinterval can elicit more or less pronounced augmentations of contractil-
ity [6]. We hypothesized that PESPAﬁb bears prognostic information in
MI survivors presenting with AF.
2. Methods
2.1. Study cohort
During the screening period of the Autonomic Regulation Trial (ART) [5], we identi-
ﬁed 32 patients suffering from acute myocardial infarction (MI) who were excluded
from the ART study analyses because of AF [5]. These patients comprised the study cohort
of the present analysis.
MI was diagnosed based on the presence of at least two of the following ﬁndings:
(1) typical chest pain for at least 20min, (2) creatine kinase above twice the upper normal
limit, and (3) ST-segment elevation≥ 0.1 mV or≥0.2 mV in at least two contiguous limb
or precordial leads, respectively. AF was diagnosed in the resting ECGs based on tracings
with no Pwaves, with ﬁbrillatorywaves of different amplitudes and duration, andwith ir-
regular ventricular response. Patients with the indication for secondary-prophylactic
cardioverter-deﬁbrillator (ICD) implantation before hospital discharge were excluded.
Written informed consent was obtained from all participants. The study protocol con-
forms to the ethical principles of the 1975 Declaration of Helsinki and was approved by
the local ethics committee.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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indexMI. Clinical follow-up appointmentswere scheduled every 6months. If a patient did
not attend a planned appointment, contact was made via telephone, mail or through the
attending general practitioner. If none of these channelswere successful, the local popula-
tion registry was contacted to either receive the patient's new address or conﬁrm that the
patient had deceased.
2.2. Measurements
Patients underwent simultaneous 30-min recordings of high resolution ECG (sampled
at 1.6 kHz in orthogonal XYZ leads, TMS International, Enschede, theNetherlands) and ﬁn-
ger photoplethysmographic non-invasive continuous arterial blood pressure monitoring
(sampled at 200 Hz with a resolution of 1 mm Hg, FMS, Amsterdam, the Netherlands).
The recordingsweremade in supine restingposition after routine administration ofmorn-
ing medication. The raw signals were veriﬁed by an experienced technician, and artifacts
were eliminated where necessary. Left ventricular ejection fraction (LVEF) was assessed
by either left ventricular angiography or by biplane echocardiography (Sonos 5500,
Hewlett Packard, Palo Alto, CA, USA), based on endsystolic and enddiastolic images from
a representative heartbeat.
2.3. Quantiﬁcation of PESPAﬁb
All QRS complexes that were not marked as artifacts (i.e. also broad QRS complexes
resulting from either ventricular premature beats or aberrantly conducted beats) were
considered in the following analysis. For each heartbeat, the average RR interval (RR)
of 17 surrounding heartbeats (RRi − 8, RRi, RRi + 8) was calculated. Each RR interval was
expressed as percentage of RR. Successive heartbeats qualiﬁed for PESPAﬁb assessment if
RRi was b80% of RR and RRi + 1 was≥140% of RR (Fig. 1A–C), in analogy of short–long se-
quences elicited by PVCs that are used to calculate PESP in patients with sinus rhythm [5].Fig. 1.Quantiﬁcation of PESPAﬁb from simultaneous ECGandblood pressure recordings. A repres
recording (C). In the selected segment of the recording, one sequence of RR intervals (denoted
140% of the average RR interval of the 17 surrounding heartbeats (RR). The line deﬁned by RRi a
panel (D), together with the formula of PESPAﬁb calculation.The systolic pressures of the pulse waves following RRi and RRi + 1 were labeled as Pi
and Pi + 1. PESPAﬁb was calculated as (Pi + 1− Pi) / (RRi + 1− RRi), i.e. by relating the
systolic pressure change to the RR interval change (Fig. 1D). If more than one RR interval
sequence qualiﬁed for PESPAﬁb evaluation, PESPAﬁb values were averaged.
2.4. Clinical data
Complete revascularization at the time of the PESPAﬁb measurement was assessed
from the cardiac catheterization reports and deﬁned as no remaining stenosis of 75% or
more in anymain coronary artery. Repeat revascularizationwas deﬁned as any percutane-
ous coronary intervention or coronary artery bypass surgery within 1 year of the index
infarction.
2.5. Statistics
Continuous variables are presented as median and inter-quartile range (IQR) and
were compared using Mann–Whitney's U test. Categorical data are expressed as absolute
frequencies and percentages. Cox proportional hazards models and receiver operating
characteristic (ROC) curves were used to assess the prognostic value of mortality predic-
tors. Survival curves were estimated with the Kaplan–Meier method and compared with
the log-rank test. Differences were considered statistically signiﬁcant if p b 0.05. All statis-
tical analyses were done using IBM SPSS Statistics 20.0 and R 3.0.1 (R Foundation for
Statistical Computing, Vienna, Austria).
3. Results
Median follow-up was 5 years. The clinical characteristics of the
study cohort are presented in Table 1. During 5 years of follow-up, 13
patients (41%) died. Of these deaths, sixwere classiﬁed as cardiac deathsentative ECG recording (A), RR interval plot calculated from theECG (B) andbloodpressure
RRi and RRi + 1) fulﬁlls the criterion that RRi is shorter than 80% and RRi + 1 is longer than










Age (years), median (IQR) 76 (73–82) 75 (70–81) 80 (73–85)
Females, n (%) 10 (31.3) 6 (31.6) 4 (30.8)
Diabetes mellitus, n (%) 13 (40.6) 7 (36.8) 6 (46.2)
History of previous MI, n (%) 4 (12.5) 3 (15.8) 1 (7.7)
CK max (U/l), median (IQR) 1193 (574–2398) 1336 (539–2878) 1193 (572–1415)
LVEF (%), median (IQR) 42 (31–51) 43 (32–58) 36 (27–49)
Creatinine (mg/dl), median (IQR) 1.2 (1.0–1.4) 1.1 (0.9–1.4) 1.3 (1.1–1.9)
NYHA I, n (%) 17 (51.5) 10 (52.6) 7 (53.8)
NYHA II, n (%) 9 (27.3) 5 (26.3) 4 (30.8)
NYHA III, n (%) 3 (9.1) 2 (10.5) 1 (7.7)
NYHA IV, n (%) 3 (9.1) 2 (10.5) 1 (7.7)
Mean heart rate (bpm), median (IQR) 74 (66–87) 72 (67–84) 81 (64–91)
Anterior infarction, n (%) 9 (28.1) 8 (42.1) 1 (7.7)
Inferior infarction, n (%) 17 (53.1) 8 (42.1) 9 (69.2)
Lateral infarction, n (%) 4 (12.5) 1 (5.3) 3 (23.1)
Paroxysmal atrial ﬁbrillation, n (%) 10 (31.1) 5 (26.3) 5 (38.5)
Persistent/permanent atrial ﬁbrillation, n (%) 2 (68.8) 14 (73.7) 8 (61.5)
Peripheral artery disease, n (%) 2 (6.3) 1 (5.3) 1 (7.7)
Therapy data
PCI, n (%) 25 (78.1) 15 (78.9) 10 (76.9)
Thrombolysis, n (%) 1 (3.1) 1 (5.3) 0 (0)
CABG, n (%) 0 (0) 0 (0) 0 (0)
No intervention possible/necessary, n (%) 6 (18.8) 3 (15.8) 3 (23.1)
Complete revascularization, n (%) 11 (34.4) 7 (36.8) 4 (30.8)
Repeat revascularization, n (%) 11 (34.4) 7 (36.8) 4 (30.8)
Aspirin, n (%) 30 (93.8) 17 (89.5) 13 (100)
Beta-blockers, n (%) 29 (90.6) 17 (89.5) 12 (92.3)
ACE Inhibitors, n (%) 29 (90.6) 16 (84.2) 13 (100)
Statins, n (%) 28 (87.5) 15 (78.9) 13 (100)
Diuretics, n (%) 23 (71.9) 12 (63.2) 11 (84.6)
Digitalis, n (%) 2 (6.3) 2 (10.5) 0 (0)
Class I/III antiarrhythmics, n (%) 0 (0) 0 (0) 0 (0)
ACE denotes angiotensin-converting enzyme; CABG, coronary artery bypass grafting; CK, creatine kinase; IQR, inter-quartile range; LVEF, left ventricular ejection fraction;NYHA,NewYork
Heart Association functional class; PCI, percutaneous coronary intervention.
Fig. 2. PESPAﬁb in survivors and non-survivors. PESPAﬁb values from individual patients are
shown as black circles. Average PESPAﬁb values and standard deviations are shown as solid
and dashed gray lines, respectively.
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dial aneurysm, one sudden cardiac death). Two deaths were classiﬁed as
non-cardiac deaths (both due to pneumonia with secondary complica-
tions). The precise cause of death of the remaining ﬁve deceased patients
is unknown.
On average, 14 (median, interquartile range 5–32) successive heart-
beat pairs met the requirements for PESPAﬁb calculation. In survivors
and non-survivors, the number was 14 (4–33) and 18 (6–32), res-
pectively. Fig. 2 shows the PESPAﬁb values of all survivors and non-
survivors. The ﬁve patients with the largest values died, while the
seven patients with the lowest values survived. The difference between
PESPAﬁb values of survivors (median 1.7, IQR −1.8–7.4) and non-
survivors (median 15.6, IQR 2.2–32.0) was statistically signiﬁcant
(p= 0.007). The area under the ROC curve (AUC) was 0.78 (95% conﬁ-
dence interval 0.61–0.94), indicating a good discrimination between
survivors and non-survivors.
In univariable Cox proportional hazards analysis, PESPAﬁb was sig-
niﬁcantly associated with mortality, while LVEF, age, the presence of
diabetes mellitus and the mean heart rate were not (Table 2). The haz-
ard ratio for a 1 mm Hg/s increase in PESPAﬁb was 1.05 (1.06–1.09, p =
0.004, see Table 2). The increase in mortality with increasing PESPAﬁb
cutoff values was almost linear over the range of observed PESPAﬁb
values (Fig. 3).
When PESPAﬁb was dichotomized at its median (4.5 mm Hg/s), pa-
tientswith larger PESPAﬁb had amortality rate of 63% (10/16), compared
to a rate of 19% (3/16) in patients with smaller PESPAﬁb. Kaplan–Meier
curves for all-cause mortality in these patient groups are depicted in
Fig. 4. The difference between groups was statistically signiﬁcant (p =
0.008). The hazard ratio for PESPAﬁb ≥ 4.5 mm Hg/s was 4.88 (1.33–
17.84, p = 0.004, see Table 2).The association of PESPAﬁb with mortality was independent from
established risk factors. The low number of events precluded us from
performing a factual multivariable Cox analysis including all candidate
prognostic parameters. However, when PESPAﬁb was entered together
with either LVEF, age, presence of diabetes mellitus or mean heart rate
in a pairwise fashion into multivariable Cox models, PESPAﬁb consistently
remained signiﬁcantly associated with mortality (Fig. 5).
Table 2
Univariable Cox regression analysis.
Variable Hazard ratio χ2 p
PESPAﬁb Per 1 mm Hg/s 1.06 (1.02–1.09) 8.37 0.004
≥4.5 mm Hg/s 4.88 (1.33–17.84) 5.73 0.017
LVEF Per % 0.96 (0.92–1.00) 2.62 0.106
≤35% 1.48 (0.48–4.53) 0.47 0.495
Presence of diabetes mellitus 1.22 (0.41–3.62) 0.12 0.725
Age Per year 1.06 (0.98–1.15) 2.08 0.149
≥65 years 1.25 (0.16–9.59) 0.04 0.833
Mean heart rate Per bpm 1.04 (0.98–1.09) 1.56 0.212
N75 bpm 2.73 (0.91–8.18) 3.23 0.072
Aﬁb denotes atrial ﬁbrillation; bpm, beats per minute; LVEF, left ventricular ejection frac-
tion; PESP, post-extrasystolic potentiation.
Fig. 4.Mortality risk over ﬁve years of patients stratiﬁed by PESPAﬁb dichotomized at the
median (4.5 mm Hg/s) is depicted. The number of patients at risk is indicated below the
graph using the same color coding.
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30-minute recording period of each patient into two consecutive 15-
minute segments that were separately analyzed. Twenty-nine patients
had short–long sequences suitable for PESPAﬁb calculation in both seg-
ments. In each segment, the patient risk was classiﬁed as high or low
by applying the PESPAﬁb dichotomy of 4.5 mm Hg/s. The risk classiﬁca-
tionwas concordant in 23 of these patients (79%), indicating reasonable
short-term reproducibility.
For the calculation of PESPAﬁb, we did not eliminate broad QRS
complexes resulting from PVCs. The average number of PVCs in the
30-minute recordings was 16. Of the short–long sequences used for
the calculation of PESPAﬁb, 8.5% were initiated by PVCs. If we excluded
PVCs from the analysis, the AUC decreased from 0.78 to 0.73. If PESPAﬁb
was calculated only based on short–long sequences initiated by PVCs,
there was no signiﬁcant association with mortality.
4. Discussion
Themainﬁndingof our study is that PESPAﬁb predicts the outcome of
post-MI patients suffering from AF. This observation is in line with the
results of our recent report [5] demonstrating that PESP is a strong predic-
tor of mortality in two independent patient cohorts with sinus rhythm,
one ofMI survivors and one of heart failure patients. Together with previ-
ous observations, our data support the concept that evaluating PESP in a
clinical setting based on non-invasive continuous blood pressure record-
ings is suitable to assess the functional status of myocardium for signs of
heart failure.
Our observation is potentially clinically important, since in AF
patients, the usual non-invasive procedures of risk stratiﬁcation are of
little if any predictive value: Heart rate variability [7], heart rate turbu-
lence [8,9], deceleration capacity of heart rate [10] and T-wave alternans
[11] can only bemeasured during sinus rhythm. Even the assessment of
LVEF during atrial ﬁbrillation lacks precision. Other risk predictors suchFig. 3. Continuous association of PESPAﬁb andmortality risk. Themortality risk (black line)
together with the 95% conﬁdence interval (gray area) is shown as a function of PESPAﬁb
cutoff value.as respiratory rate [12–14] or periodic repolarization dynamics [15] are
theoretically applicable in AF patients. However, their prognostic value
in AF has not been investigated yet and is thus unknown. A novel
non-invasive method to predict mortality risk of MI patients with AF
thus covers an important unmet clinical need.
PESP and its derivative PESPAﬁb aremanifestations of themyocardial
force–interval relationship (FIR). It has been shown that the FIR is a
major determinant of the beat-to-beat blood pressure variability during
atrial ﬁbrillation [16–19].
The FIR is determined to a large extent by themagnitude of intracel-
lular calcium transients in the cardiomyocytes [20]. Most experimental
studies have determined FIR (typically expressed as its inverse, the
force–frequency relation, FFR) under steady-state conditions by pacing
the myocardium at different frequencies. In the normal heart beating
within the physiological range of heart rates, this steady-state contrac-
tility increases with higher heart rates (i.e., with shorter beat-to-beat
intervals). A blunted or even inverse FFR is a hallmark of failingmyocar-
dium [21]. The FIR, however, also manifests at disequilibriumwhen theFig. 5. Analysis for possible confounding factors. The hazard ratio and 95% conﬁdence in-
terval for PESPAﬁb obtained from univariable Cox analysis as well as those obtained from
multivariable analyses including one of several other risk predictors (LVEF, diabetes, age,
mean heart rate) are shown. The gray dashed line indicates a hazard ratio of one. PESPAﬁb
remained a signiﬁcant predictor of mortality in all multivariable models.
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[22] or, as investigated in the present study, by the highly-variable beat-
to-beat cycle lengths during AF [16].
The increased contractility of a post-extrasystolic heartbeat can be
understood on the basis of the underlying calcium signaling processes
[23,24]. A premature heartbeat results in calcium inﬂux via the plasma
membrane at a time point when a relevant fraction of the ryanodine re-
ceptor calcium channels in themembrane of the sarcoplasmic reticulum
(SR) is still refractory. Consequently, calcium release through the
ryanodine receptors is reduced compared to normal heartbeats. In the
post-extrasystolic pause, the SR calcium content is further increased
due to re-sequestration by the sarco-endoplasmatic reticulum calci-
um ATPase (SERCA). The increased SR calcium content available for
release at the post-extrasystolic heartbeat results in an augmented
post-extrasystolic contraction.
In the failingmyocardium, the SR calcium content is reduced, as sev-
eral integral compounds of the calcium cycling system are dysregulated
(e.g. leakiness of ryanodine receptors and reduced SERCA activity) [21].
Starting from this lower steady state, the relative increase of SR calcium
content during the post-extrasystolic pause and, consequently, the rel-
ative potentiation of post-extrasystolic calcium release are augmented
as compared to normal hearts. This is supported by bothmodeling stud-
ies and experimental data. For example, in a computational model of
myocardial calcium handling, an attenuation of SERCA activity resulted
in increased PESP [25]. In a mouse model, overexpression of the SERCA
inhibitor phospholamban was associated with a reduced SR calcium
content and increased PESP [26].
In the present study, as in our previous study [5], a steeper-than-
normal FIR (indicated by larger-than-normal PESP or PESPAﬁb) was as-
sociated with an increased mortality. Although at ﬁrst sight counterin-
tuitive, it is well established that in the failing heart, PESP is typically
enhanced as compared to normal ventricles [27–31].
Further investigation of PESPAﬁb in various clinical conditions is
needed. In particular, it would be appropriate to know whether treat-
ment of acutely decompensated heart failure is accompanied by regres-
sion of PESPAﬁb values. Moreover, since the pathophysiological concept
of PESPAﬁb is closely related to that of PESP, a comparison of these two
parameters in patients who have both sinus rhythm and atrial ﬁbrilla-
tion (e.g. before and after cardioversion of persistent AF or in patients
with paroxysmal AF) might help for improving our understanding of
the correlation of these two phenomena.
5. Limitations
The main limitations of our study are the small sample size and the
retrospective nature of the analysis, which call for a prospective valida-
tion of the approach in a larger patient cohort.
PESPAﬁbwas assessed on the basis of systolic blood pressure changes.
Systolic blood pressure is not solely determined by the contractile state
of the heart, but also affected by the compliance of the vascular system.
Therefore, increased peripheral arterial resistance might contribute to
the steep PESPAﬁb found in high-risk patients. The maximum systolic
rise of left ventricular pressure (dP/dtmax) would bemore closely corre-
latedwithmyocardial contractility than systolic blood pressure; howev-
er, determining this parameter would require invasive catheterization
of the left ventricle. If PESPAﬁb was calculated based on dP/dtmax taken
from the non-invasive peripheral blood pressure recordings, however,
we still observed a signiﬁcant association with mortality, although
reaching slightly lower statistical signiﬁcance levels (data not shown).
Regional analysis of post-extrasystolic myocardial contractility has
been used as a tool to identify “stunned” or “hibernating”myocardial re-
gions, that are hypocontractile at rest due to ischemia andmight beneﬁt
from revascularization [32]. The presence of such regionsmight also in-
ﬂuence PESPAﬁbmeasured at the blood pressure level. A substantial frac-
tion of the included patients were not completely revascularized at the
time of the PESPAﬁb assessment, or underwent repeat revascularizationswithin one year (see Table 1). However, when either complete revascu-
larization status or repeat revascularization was included in the Cox
model together with PESPAﬁb, only PESPAﬁb remained in the model as
a signiﬁcant predictor of mortality (data not shown). We conclude
that regional ischemia is not a relevant confounder in our data.
We assessed PESPAﬁb during the acute hospitalization, on median
8 days (interquartile range 4–11) after the index MI. It is possible that
a different timing (e.g. in the stable phase N 30 days after the MI)
might inﬂuence the predictive value of the test.
The criteria for the identiﬁcation of suitable heartbeat pairs qualiﬁed
for PESPAﬁb assessment (RRi as b80% and RRi + 1 as≥140% of RR, where
RR is calculated as mean of 17 surrounding RR intervals) were devel-
oped in our data set to optimize the signal-to-noise ratio. These criteria
might not be universally optimum.
6. Conclusions
PESPAﬁb, a measure for the force–interval relationship in patients
with AF, can be derived from simultaneous ECG and blood pressure re-
cordings. The results of this pilot study indicate that PESPAﬁb may be
useful to predict adverse outcome in survivors of myocardial infarction
suffering from AF.
Conﬂict of interest
None of the authors have any conﬂict of interest.
Acknowledgments
This work was supported by the Bundesministerium für Bildung,
Wissenschaft, Forschung und Technologie (13N/7073/7) and by the
Deutsche Forschungsgemeinschaft (Si 1747/1-1). The sponsors had no
role in the study design, data collection, data analysis, data interpreta-
tion, or writing of the report.
References
[1] O. Langendorff, Ueber elektrische Reizung des Herzens, Du-Bois-Reymond's Archiv.
Fur Physiologie 8 (1885) 284–287.
[2] O. Langendorff, Untersuchungen am überlebenden Säugetierherzen III. Abhandlung:
Unregelmäßigkeiten des Herzschlages und ihre Ausgleichung, Pﬂugers Arch.
Gesamte Physiol. 70 (1898) 473–486.
[3] A. Bornstein, Die Postextrasystole, Zbl. Physiol. 20 (1906) 401–405.
[4] B.F. Hoffman, E. Bindler, E.E. Suckling, Postextrasystolic potentiation of contraction
in cardiac muscle, Am. J. Physiol. 185 (1956) 95–102.
[5] D. Sinnecker, R. Dirschinger, P. Barthel, A. Müller, A. Morley-Davies, A. Hapfelmeier,
M. Dommasch, K.M. Huster, G. Hasenfuss, K.L. Laugwitz, M. Malik, G. Schmidt, Post-
extrasystolic blood pressure potentiation predicts poor outcome of cardiac patients,
J. Am. Heart Assoc. 3 (3) (2014) e000857.
[6] K.D. Varian, Y. Xu, C.A.A. Torres, M.M. Monasky, P.M.L. Janssen, A random cycle
length approach for assessment of myocardial contraction in isolated rabbit myo-
cardium, Am. J. Physiol. Heart Circ. Physiol. 279 (2009) H1940–H1948.
[7] H. Huikuri, P.K. Stein, Clinical application of heart rate variability after acute myocar-
dial infarction, Front. Physiol. 3 (2012) 41.
[8] G. Schmidt, M. Malik, P. Barthel, R. Schneider, K. Ulm, L. Rolnitzky, A.J. Camm, J.T.
Bigger Jr., A. Schömig, Heart-rate turbulence after ventricular premature beats as a
predictor of mortality after acute myocardial infarction, Lancet 353 (1999)
1390–1396.
[9] A. Bauer, M. Malik, G. Schmidt, P. Barthel, H. Bonnemeier, I. Cygankiewicz, P. Guzik,
F. Lombardi, A. Müller, A. Oto, R. Schneider, M. Watanabe, D. Wichterle, W. Zareba,
Heart rate turbulence: standards of measurement, physiological interpretation,
and clinical use, J. Am. Coll. Cardiol. 52 (2008) 1353–1356.
[10] A. Bauer, J.W. Kantelhardt, P. Barthel, R. Schneider, T. Mäkikallio, K. Ulm, K.
Hnatkova, A. Schömig, H. Huikuri, A. Bunde, M. Malik, G. Schmidt, Deceleration ca-
pacity of heart rate as a predictor of mortality after myocardial infarction: cohort
study, Lancet 367 (2006) 1674–1681.
[11] R.L. Verrier, T. Klingenheben, M. Malik, N. El-Sherif, D.V. Exner, S.H. Hohnloser, T.
Ikeda, J.P. Martínez, S.M. Narayan, T. Nieminen, D.S. Rosenbaum, Microvolt T-wave
alternans. Physiological basis, methods of measurement, and clinical utility— consen-
sus guideline by international society for Holter and noninvasive electrocardiology, J.
Am. Coll. Cardiol. 58 (2011) 1309–1324.
[12] P. Barthel, R. Wensel, A. Bauer, A. Müller, P. Wolf, K. Ulm, K.M. Huster, D.P. Francis,
M.Malik, Respiratory rate predicts outcome after acutemyocardial infarction: a pro-
spective cohort study, Eur. Heart J. 34 (2013) 1644–1650.
320 D. Sinnecker et al. / International Journal of Cardiology 182 (2015) 315–320[13] M. Dommasch, D. Sinnecker, P. Barthel, A. Müller, R.J. Dirschinger, A. Hapfelmeier,
K.M. Huster, K.L. Laugwitz, M. Malik, G. Schmidt, Nocturnal respiratory rate predicts
non-sudden cardiac death in survivors of acute myocardial infarction, J. Am. Coll.
Cardiol. 63 (2014) 2432–2433.
[14] D. Sinnecker, M. Dommasch, P. Barthel, A. Müller, R.J. Dirschinger, A. Hapfelmeier,
K.M. Huster, K.L. Laugwitz, M. Malik, G. Schmidt, Assessment of mean respiratory
rate from ECG recordings for risk stratiﬁcation after myocardial infarction, J.
Electrocardiol 47 (5) (2014) 700–704.
[15] K.D. Rizas, T. Nieminen, P. Barthel, C.S. Zürn, M. Kähönen, J. Viik, T. Lehtimäki, K.
Nikus, C. Eick, T.O. Greiner, H.P. Wendel, P. Seizer, J. Schreieck, M. Gawaz, G.
Schmidt, A. Bauer, Sympathetic activity-associated periodic repolarization dynamics
predict mortality following myocardial infarction, J. Clin. Invest. 124 (2014)
1770–1780.
[16] S.M.C. Hardman, M.I.M. Noble, W.A. Seed, Postextrasystolic potentiation and its
contribution to the beat-to-beat variation of the pulse during atrial ﬁbrillation,
Circulation 86 (1992) 1223–1232.
[17] S.M.C. Hardman, K.P. Pfeiffer, T. Kenner,M.I.M. Noble,W.A. Seed, Analysis of left ven-
tricular contractile behaviour during atrial ﬁbrillation, Basic Res. Cardiol. 98 (1994)
438–455.
[18] S.M.C. Hardman, M.I.M. Noble, T. Biggs, A. Seed, Evidence for an inﬂuence of me-
chanical restitution on beat-to-beat variations in haemodynamics during chronic
atrial ﬁbrillation in patients, Cardiovasc. Res. 38 (1998) 82–90.
[19] S. Suzuki, J. Araki, T. Morita, S. Mohri, T. Mikane, H. Yamaguchi, S. Sano, T. Ohe, M.
Hirakawa, H. Suga, Ventricular contractility in atrial ﬁbrillation is predictable by me-
chanical restitution and potentiation, Am. J. Physiol. 275 (1998) H1513–H1519.
[20] M. Endoh, Force–frequency relationship in intact mammalian ventricular myocardi-
um: physiological and pathophysiological relevance, Eur. J. Pharmacol. 500 (2004)
73–86.
[21] G. Hasenfuss, B. Pieske, Calcium cycling in congestive heart failure, J. Mol. Cell.
Cardiol. 34 (2002) 951–969.
[22] S.M.C. Hardman, Clinical implications of the interval–force relationship of the heart,
Postgrad. Med. J. 70 (1994) 553–557.[23] W.G. Wier, D.T. Yue, Intracellular calcium transients underlying the short-term
force–interval relationship in ferret ventricular myocardium, J. Physiol. 376 (1986)
507–530.
[24] J.J. Rice, M.S. Jafri, R.L. Winslow, Modeling short-term interval–force relations in car-
diac muscle, Am. J. Physiol. Heart Circ. Physiol. 278 (2000) H919–H931.
[25] G. Iribe, P. Kohl, D. Noble, Modulatory effect of calmodulin-dependent kinase II
(CaMKII) on sarcoplasmic reticulum Ca2+ handling and interval–force relations: a
modeling study, Phil. Trans. R. Soc. A 364 (2006) 1107–1133.
[26] B.D. Hoit, D.A. Tramuta, V.J. Kadambi, R. Dash, N. Ball, E.G. Kranias, R.A.Walsh, Inﬂuence
of transgenic overexpression of phospholamban on postextrasystolic potentiation, J.
Mol. Cell. Cardiol. 31 (1999) 2007–2015.
[27] W. Beck, E. Chesler, V. Schrire, Postextrasystolic ventricular pressure responses,
Circulation 44 (1971) 523–533.
[28] J. Kvasnicka, B. Liander, H. Broman, E. Varnauskas, Quantitative evaluation of
postectopic beats in the normal and failing human heart using indices derived
from catheter-tip manometer readings, Cardiovasc. Res. 9 (1975) 336–341.
[29] J.P. Merillon, G. Motte, M.C. Aumont, C. Masquet, Y. Lecarpentier, R. Gourgon, Post-
extrasystolic left ventricular peak pressure with and without left ventricular failure,
Cardiovasc. Res. 13 (1979) 338–344.
[30] W.A. Seed, M.I. Noble, J.M. Walker, G.A. Miller, J. Pidgeon, D. Redwood, R. Wanless,
M.R. Franz, M. Schoettler, J. Schaefer, Relationships between beat-to-beat interval
and the strength of contraction in the healthy and diseased human heart, Circula-
tion 70 (1984) 799–805.
[31] A. Voss, V. Baier, A. Schumann, A. Hasart, F. Reinsperger, A. Schirdewan, K.J. Osterziel,
U. Leder, Postextrasystolic regulation patterns of blood pressure and heart rate in
patients with idiopathic dilated cardiomyopathy, J. Physiol. 538 (1) (2002)
271–278.
[32] M.W. Cooper, Postextrasystolic potentiation: do we really know what it means and
how to use it? Circulation 88 (1993) 2962–2971.
